PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26224876-8	2015	Knock-in mice expressing an uncleavable p120 RasGAP mutant showed exaggerated NF-kappaB activation when their epidermis was treated with anthralin, a drug used for the treatment of psoriasis.	Anthralin	137-146	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	78-87	
8666828-0	1996	Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes.	Anthralin	20-29	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	61-71	
8666828-4	1996	In this study, we show that at little as 10 microM anthralin can activate a prototypic form of transcription factor NF-(kappa)B, a central transcriptional regulator of inflammatory and immune responses.	Anthralin	51-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-127	
8666828-5	1996	Two different lines of evidence show that ROIs, in particular H2O2, are second messengers for the anthralin-induced NF-(kappa)B activation.	Anthralin	98-107	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-127	
8666828-8	1996	Our data suggest that ROI-induced NF-(kappa)B plays a role in the anti-psoriatic activity of the drug anthralin.	Anthralin	102-111	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	34-45